ArticleBlood advances2019
Multiple functional variants in the
Open access · goldAbstract read
In one paragraph
Article in Blood advances, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 8 citations in OpenAlex.
- Advances in graft-versus-host disease: emerging therapeutic strategies, biomarker discoveries, and innovative treatment approaches.Frontiers in immunology · 2026Review
- Whole-Genome Sequencing Analyses Reveal the Whip-like Tail Formation, Innate Immune Evolution, and DNA Repair Mechanisms ofAnimals : an open access journal from MDPI · 2024Article
- Associations of minor histocompatibility antigens with outcomes following allogeneic hematopoietic cell transplantation.American journal of hematology · 2023Article
- Post-haematopoietic cell transplantation outcomes: why ST2 became a 'golden nugget' biomarker.British journal of haematology · 2021Review
- Biomarkers for Allogeneic HCT Outcomes.Frontiers in immunology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 7 institutions in 1 country.
Ezgi KaraesmenDivision of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, OH.ORCID 0000-0002-0881-7424
Theresa HahnDepartment of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY.
Alexander James DileDepartment of Pediatrics, Indiana University School of Medicine, Indianapolis, IN.ORCID 0000-0002-1401-9744
Abbas A RizviDivision of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, OH.
Junke WangDivision of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, OH.
Tao WangCenter for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI.
Michael D HaagensonCenter for International Blood and Marrow Transplant Research, Minneapolis, MN.
Leah PreusDivision of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, OH.
Qianqian ZhuDepartment of Biostatistics, Roswell Park Comprehensive Cancer Center, Buffalo, NY.ORCID 0000-0003-2516-6675
Qian LiuDepartment of Biostatistics, Roswell Park Comprehensive Cancer Center, Buffalo, NY.
Li YanDepartment of Biostatistics, Roswell Park Comprehensive Cancer Center, Buffalo, NY.
Song LiuDepartment of Biostatistics, Roswell Park Comprehensive Cancer Center, Buffalo, NY.
Christopher A HaimanDepartment of Preventive Medicine, University of Southern California, Los Angeles, CA.
Daniel StramDepartment of Preventive Medicine, University of Southern California, Los Angeles, CA.ORCID 0000-0001-7099-9022
Loreall PoolerDepartment of Preventive Medicine, University of Southern California, Los Angeles, CA.ORCID 0000-0001-5388-6640
Xin ShengDepartment of Preventive Medicine, University of Southern California, Los Angeles, CA.ORCID 0000-0002-6844-2740
David Van Den BergDepartment of Preventive Medicine, University of Southern California, Los Angeles, CA.
Guy BrockDepartment of Biomedical Informatics, The Ohio State University, Columbus, OH.
Amy WebbDepartment of Biomedical Informatics, The Ohio State University, Columbus, OH.
Philip L McCarthyDepartment of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY.ORCID 0000-0002-9577-3879
Marcelo C PasquiniCenter for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI.
Stephen R SpellmanCenter for International Blood and Marrow Transplant Research, Minneapolis, MN.
Stephanie J LeeClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; and.ORCID 0000-0003-2600-6390
Sophie PaczesnyDepartment of Pediatrics, Indiana University School of Medicine, Indianapolis, IN.ORCID 0000-0001-5571-2775
Lara E Sucheston-CampbellDivision of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, OH.
The Ohio State University · USRoswell Park Comprehensive Cancer Center · USUniversity of Southern California · USIndiana University School of MedicineMedical College of Wisconsin · USNational Marrow Donor Program · USFred Hutch Cancer Center · US
Funding
Data Resource for Analyzing Blood &Marrow TransplantsU24CA076518 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Amy M Moskop, Bronwen Shaw · 1998 to 2026
$105.2MEasy-to-read Informed Consent for HCT Clinical TrialsU10HL069294 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI HOROWITZ, MARY MARESCA · 2011 to 2016
$43.8MThe OSU Center for Clinical and Translational Science: Advancing Today's Discoveries to Improve HealthUL1TR002733 · NCATS · OHIO STATE UNIVERSITY · PI RINGEL, MATTHEW D · 2018 to 2022
$28.9MGenetic susceptibility to unrelated donor stem cell transplant-related mortalityR01HL102278 · NHLBI · ROSWELL PARK CANCER INSTITUTE CORP · PI HAHN, THERESA E, SUCHESTON-CAMPBELL, LARA · 2010 to 2013
$5.0MTranslating Novel Drug-Targetable Biomarkers to Treat Graft versus Host DiseaseR01CA168814 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI PACZESNY, SOPHIE · 2013 to 2024
$3.0MBridging Pediatric and Adult Biomarkers of Graft-Versus-Host-DiseaseR01HD074587 · NICHD · INDIANA UNIVERSITY INDIANAPOLIS · PI PACZESNY, SOPHIE, RENBARGER, JAMIE L · 2013 to 2017
$2.4MProject 2: Biomarkers of endothelial dysfunction in pediatric patients receiving high intensity chemotherapy/irradiationU54HD090215 · NICHD · INDIANA UNIVERSITY INDIANAPOLIS · PI RENBARGER, JAMIE L · 2016 to 2018
$2.3MGenetic susceptibility to acute lymphocytic and myeloid leukemiaR03CA188733 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI HAHN, THERESA E, SUCHESTON-CAMPBELL, LARA · 2015 to 2016
$176kNCATS NIH HHS UL1 TR002733NCI NIH HHS R01 CA168814NCI NIH HHS R03 CA188733NCI NIH HHS U24 CA076518NHLBI NIH HHS R01 HL102278NHLBI NIH HHS U10 HL069294NICHD NIH HHS R01 HD074587NICHD NIH HHS U54 HD090215
Abstract
Graft-versus-host disease (GVHD) and infections are the 2 main causes of death without relapse after allogeneic hematopoietic cell transplantation (HCT). Elevated soluble serum simulation-2 (sST2), the product of
Indexed as
BiomarkersGenetic Predisposition to DiseaseGenetic VariationAdultComputational BiologyFemaleGenotypeGraft vs Host DiseaseHematopoietic Stem Cell TransplantationHumansInterleukin-1 Receptor-Like 1 ProteinLinkage DisequilibriumMaleMiddle AgedMolecular Sequence AnnotationPolymorphism, Single NucleotideBiomarkersIL1RL1 protein, humanInterleukin-1 Receptor-Like 1 Protein
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.